Full Press Release Details
Announces Positive Long-Term Follow-Up Data from Phase 2 Vascular Access Trial
Durham, N.C. - April 20, 2021 -
Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at
commercial scale, today announced that five-year data from a Phase 2 clinical trial of patients receiving the human acellular vessels
(HAV) for arteriovenous (AV) access in hemodialysis suggest the long-term durability and functional hemodialysis access of the HAV.
Secondary patency was 58.2% (95% CI; 39.2-73.1%)
at five years, after censoring for deaths and withdrawals. The data also showed a substantial reduction in infection rates compared to
published rates for the current standard of care ePTFE. Long-term explant samples showed progressive host cell remodeling with the formation
of a neo-adventitia, the vessel wall containing vascular smooth muscle cells and lumen of HAV was lined with endothelial cells. In the
five years after HAV implantation, no infections of the HAV were noted and no clinical evidence of immunological rejection were observed
in this Phase 2 trial.
"These long-term data reinforce the
initial results and help demonstrate that the HAV has the potential to provide durable, functional hemodialysis access, and repopulate
with the patient's own cells while maintaining a robust safety profile," said Jeffrey Lawson, M.D., Ph.D., Chief Surgical
Officer of Humacyte. "We are encouraged by these results, which buttress our robust
body of evidence supporting the potential of the HAV to be a pioneering engineered, off-the shelf, regenerative human tissue, and look
forward to the continued evaluation of HAV in our ongoing trials in vascular access, vascular trauma and peripheral arterial disease."
The prospective Phase 2 trials evaluated HAV
in adult patients with end-stage renal disease undergoing hemodialysis at six sites in the U.S. and Poland. The long-term follow-up data
is based upon the cohort of patients in Poland who continued routine dialysis with HAV and were followed for conduit status every three
months following completion of the main portion of the study (month 24) through at least five years, the longest-term follow-up to any
trial of any implanted engineered human connective tissue.
The data were presented in an oral presentation
at the Charing Cross (CX) International Symposium by Dr. Lawson and have been submitted for publication in a peer-reviewed
journal. The presentation can be accessed on Humacyte's website, www.Humacyte.com.
On February 17, 2021, Alpha Healthcare Acquisition
Corp. (Nasdaq: AHAC) ("AHAC"), a special purpose acquisition company, and Humacyte announced the execution of a definitive
business combination agreement along with a fully committed $175 million PIPE financing agreement.
Human Acellular Vessels (HAV) are engineered
off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV is intended to overcome
long-standing limitations in vessel tissue repair and replacement - it can be manufactured at commercial scale, it eliminates the
need for harvesting a vessel from a patient, and clinical evidence suggests that it is non-immunogenic, infection-resistant, and can
become durable living tissue. HAV is currently being evaluated in two Phase 3 trials in AV access and a Phase 2/3 trial for vascular
trauma, and has been used in more than 430 patient implantations. It is the first product to receive Regenerative Medicine Advanced Therapy
(RMAT) designation from the U.S. Food and Drug Administration, and has also received FDA Fast Track designation.
developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to
improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat
a wide range of diseases, injuries and chronic conditions. Humacyte's initial opportunity, a portfolio of human acellular vessels
(HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous
access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts,
pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte's HAVs were the
first product to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority
designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
About Alpha Healthcare
Alpha Healthcare Acquisition Corp. (ticker: AHAC) is a special purpose acquisition company formed for the purpose of effecting a
business combination with one or more businesses in the healthcare sector ("AHAC"). The company was founded by Mr. Rajiv
Shukla who has two decades of buyouts, investments and operations experience in the healthcare industry. Mr. Shukla previously served
as Chairman and Chief Executive Officer of Constellation Alpha Capital Corp., a Nasdaq-listed special purpose acquisition company,
that merged with DermTech, Inc (ticker: DMTK) in August 2019. On February 17, 2021, AHAC announced a definitive agreement to merge
with Humacyte, Inc. along with a concurrent fully committed PIPE placement of $175 million of AHAC common shares at a price of $10.00
Important Information
About the Merger and Where to Find It
A full description of the terms of the business combination will be provided in a registration statement on Form S-4 filed with the
SEC by AHAC that includes a prospectus with respect to the Combined Company's securities to be issued in connection with the business
combination and a proxy statement with respect to the shareholder meeting of AHAC to vote on the business combination. AHAC urges its
investors, shareholders and other interested persons to read, the preliminary proxy statement/ prospectus as well as other documents
filed with the SEC because these documents will contain important information about AHAC, Humacyte and the business combination. After
the registration statement is declared effective, the definitive proxy statement/prospectus included in the registration statement will
be mailed to shareholders of AHAC as of a record date to be established for voting on the proposed business combination. Shareholders
will also be able to obtain a copy of the Form S-4, including the proxy statement/prospectus, and other documents filed with the SEC
without charge, by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas, 5th Floor,
New York, New York 10036. The preliminary and definitive proxy statement/prospectus to be included in the registration statement,
can also be obtained, without charge, at the SEC's website (www.sec.gov).
AHAC and Humacyte and their respective directors and executive officers may be considered participants in the solicitation of proxies
with respect to the proposed business combination described in this press release under the rules of the SEC. Information about the directors
and executive officers of AHAC is set forth in AHAC's final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities
Act of 1933, as amended (the "Securities Act") on September 17, 2020, and is available free of charge at the SEC's
website at www.sec.gov or by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas,
5th Floor, New York, New York 10036. Information regarding the persons who may, under the rules of the SEC,
be deemed participants in the solicitation of the AHAC shareholders in connection with the proposed business combination will be set
forth in the registration statement containing the proxy statement/prospectus for the proposed business combination. These documents
can be obtained free of charge from the sources indicated above.
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available.
In some cases, you can identify forward-looking statements by the following words: "may," "will," "could,"
"would," "should," "expect," "intend," "plan," "anticipate,"
"believe," "estimate," "predict," "project," "potential," "continue,"
"ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain
these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance
or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we
believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these
statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot
be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the initiation, timing,
progress and results of our clinical trials; the anticipated characteristics and performance of our HAVs, our ability to successfully
complete, clinical trials for our HAVs; the anticipated benefits of our HAVs relative to existing alternatives; the commercialization
of our HAVs and our ability to manufacture at commercial scale; the implementation of our business model, strategic plans for our business;
the scope of protection we are able to establish and maintain for intellectual property rights covering our HAVs and related technology;
the timing or likelihood of regulatory filings and approvals; timing, scope and rate of reimbursement for our HAVs; our estimated available
market opportunity; the proposed business combination, including the timing and structure of the business combination, the proceeds of
the business combination, and the benefits of the business combination. We cannot assure you that the forward-looking statements in this
press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties
that could cause actual results to differ materially from expected results, including, among others, the ability to complete the business
combination due to the failure to obtain approval from AHAC's shareholders or satisfy other closing conditions in the Business
Combination Agreement, the occurrence of any event that could give rise to the termination of the Business Combination Agreement, the
ability to recognize the anticipated benefits of the business combination, the outcome of any legal proceedings that may be instituted
against AHAC or Humacyte following announcement of the proposed business combination and related transactions, the impact of COVID-19
on Humacyte's business and/or the ability of the parties to complete the business combination, the ability to obtain or maintain
the listing AHAC's common stock on Nasdaq following the proposed business combination, costs related to the proposed business combination,
changes in applicable laws or regulations, the possibility that Alpha Healthcare Acquisition Corp. or Humacyte may be adversely affected
by other economic, business, and/or competitive factors, and other risks and uncertainties, including those to be included under the
header "Risk Factors" in the registration statement on Form S-4 filed by AHAC with the SEC and those included under the header